VolitionRx (VNRX) – Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for VolitionRx (NYSE: VNRX):

• 12/14/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 12/10/2024 – VolitionRx had its “buy” rating reaffirmed by analysts at D. Boral Capital. They now have a $5.00 price target on the stock.
• 12/6/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/28/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/22/2024 – VolitionRx had its “hold” rating reaffirmed by analysts at Benchmark Co..
• 11/20/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/12/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 11/4/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/27/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.
• 10/19/2024 – VolitionRx is now covered by analysts at StockNews.com. They set a “sell” rating on the stock.

VolitionRx Stock Down 7.4 %

VolitionRx stock opened at $0.57 on Monday. The firm has a market capitalization of $52.36 million, a PE ratio of -1.57 and a beta of 1.17. VolitionRx Limited has a 52 week low of $0.43 and a 52 week high of $1.23. The firm’s 50-day simple moving average is $0.68 and its 200 day simple moving average is $0.66.

Insider Buying and Selling

In other news, CEO Cameron John Reynolds acquired 139,811 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average cost of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now owns 617,085 shares of the company’s stock, valued at $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 358,266 shares of company stock worth $204,212. 12.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Geode Capital Management LLC grew its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 15.1% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 730,448 shares of the company’s stock after acquiring an additional 95,900 shares during the period. Geode Capital Management LLC owned about 0.79% of VolitionRx worth $439,000 as of its most recent SEC filing. Institutional investors and hedge funds own 8.09% of the company’s stock.

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.